Immuron IMRN Stock
Immuron Price Chart
Immuron IMRN Financial and Trading Overview
Immuron stock price | 1.78 USD |
Previous Close | 2 USD |
Open | 1.96 USD |
Bid | 0 USD x 1000 |
Ask | 0 USD x 1000 |
Day's Range | 1.95 - 2.1 USD |
52 Week Range | 1.39 - 3.21 USD |
Volume | 7.28K USD |
Avg. Volume | 360.83K USD |
Market Cap | 12.43M USD |
Beta (5Y Monthly) | 1.293103 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.81 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
IMRN Valuation Measures
Enterprise Value | -7504217 USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 11.117654 |
Price/Book (mrq) | 0.54569894 |
Enterprise Value/Revenue | -6.713 |
Enterprise Value/EBITDA | 2.443 |
Trading Information
Immuron Stock Price History
Beta (5Y Monthly) | 1.293103 |
52-Week Change | -23.68% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.21 USD |
52 Week Low | 1.39 USD |
50-Day Moving Average | 2.08 USD |
200-Day Moving Average | 2.06 USD |
IMRN Share Statistics
Avg. Volume (3 month) | 360.83K USD |
Avg. Daily Volume (10-Days) | 14.67K USD |
Shares Outstanding | 5.69M |
Float | 4.76M |
Short Ratio | 0.05 |
% Held by Insiders | 0% |
% Held by Institutions | 1.67% |
Shares Short | 48.17K |
Short % of Float | N/A |
Short % of Shares Outstanding | 0.85% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | -270.26% |
Operating Margin (ttm) | -275.20% |
Gross Margin | 90.20% |
EBITDA Margin | -274.80% |
Management Effectiveness
Return on Assets (ttm) | -7.93% |
Return on Equity (ttm) | -13.29% |
Income Statement
Revenue (ttm) | 1.12M USD |
Revenue Per Share (ttm) | 0.2 USD |
Quarterly Revenue Growth (yoy) | 152.69% |
Gross Profit (ttm) | 523.5K USD |
EBITDA | -3072019 USD |
Net Income Avi to Common (ttm) | -3021183 USD |
Diluted EPS (ttm) | -0.39 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 19.14M USD |
Total Cash Per Share (mrq) | 3.36 USD |
Total Debt (mrq) | 192.79K USD |
Total Debt/Equity (mrq) | 0.91 USD |
Current Ratio (mrq) | 12.111 |
Book Value Per Share (mrq) | 3.72 |
Cash Flow Statement
Operating Cash Flow (ttm) | -1812637 USD |
Levered Free Cash Flow (ttm) | -1213996 USD |
Profile of Immuron
Country | United States |
State | VIC |
City | Carlton |
Address | 62 Lygon Street |
ZIP | 3053 |
Phone | 61 3 9824 5254 |
Website | https://www.immuron.com.au |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 5 |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Q&A For Immuron Stock
What is a current IMRN stock price?
Immuron IMRN stock price today per share is 1.78 USD.
How to purchase Immuron stock?
You can buy IMRN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immuron?
The stock symbol or ticker of Immuron is IMRN.
Which industry does the Immuron company belong to?
The Immuron industry is Biotechnology.
How many shares does Immuron have in circulation?
The max supply of Immuron shares is 5.73M.
What is Immuron Price to Earnings Ratio (PE Ratio)?
Immuron PE Ratio is now.
What was Immuron earnings per share over the trailing 12 months (TTM)?
Immuron EPS is -0.81 USD over the trailing 12 months.
Which sector does the Immuron company belong to?
The Immuron sector is Healthcare.
Immuron IMRN included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Capital Market Composite RCMP | 92.16 USD — |
-4.45
|
— — | 89.57 USD — | 93.85 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}